NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading RLMD? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth bet, as RLMD operates in the healthcare sector with potential upside tied to clinical trials. However, the current thesis state is cautious due to recent earnings misses and mixed management priorities.
The market appears to have priced in low expectations given RLMD's ongoing losses and recent financial struggles. Investors may be anticipating further challenges, especially with the elevated risk of future earnings misses.
Fundamentals are likely to remain weak in the near term, as RLMD continues to face operating losses and cash burn. Management has consistently stated the need to manage these losses, but the mixed progress on key priorities raises concerns.
The long-term thesis hinges on sector performance, particularly the results of major players like VRTX, REGN, and ARGX. Positive momentum in the healthcare sector could provide a lift, but any negative shifts in guidance from these companies could adversely affect RLMD.
In the next 1 to 3 years, RLMD's outlook is uncertain, with significant risks and mixed signals from management. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. A sharp drop in RLMD's price suggests a repricing of the thesis. This decline may indicate that the market is reassessing the reasons to own the stock. Recent financial performance remains below its industry peers, which is concerning.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show how well the company is doing financially.
Confirms one read:Earnings report shows revenue growth or reduced cash burn.
Confirms the other:Earnings report shows continued losses and high cash burn.
Why it matters: Earnings results will show financial health and operational progress. A miss could hurt stock price.
Confirms one read:Earnings were better than expected. This shows good financial results.
Confirms the other:Earnings were worse than expected. This shows ongoing financial problems.
Why it matters: High cash burn may mean ongoing money problems. This could affect how investors feel.
Confirms:Cash used in operating activities for Q2 is less than $15 million.
Disproves:Cash used in operating activities for Q2 is more than $20 million.
Why it matters: Starting this program is important for Relmada. It could help investors feel more confident. It shows they are making progress on a possible top therapy for bladder cancer.
Confirms:The company announces the start of the Phase 3 RESCUE program for NDV-01.
Disproves:The company delays the initiation of the Phase 3 RESCUE program beyond mid-2026.
Why it matters: Updates on the Phase 2 trials will show progress in a key growth area for the company.
Confirms:A press release shows good results from the Phase 2 trials.
Disproves:No updates or negative results reported from the Phase 2 trials.
Why it matters: Raising money is important. It helps fund operations and clinical trials.
Confirms:A private placement raised more than $10M successfully.
Disproves:No announcement or failure to raise capital as planned.
Why it matters: If granted, this patent could help NDV-01 in the market. It would also extend its exclusivity.
Confirms:The USPTO grants the provisional patent for NDV-01.
Disproves:The patent application may be rejected or delayed.
